TNFSF14 and acute respiratory distress syndrome: Another important clinical trial (with 83 ARDS patients) on mAbs that is important to mention is of CERC-002, a neutralizing agent against TNFSF14, which proved to have significant activity in reducing mortality in the treatment group compared to the placebo group.